GU Cancers 2019 | AdRad safety results: radium-233/VMAT RT in the first-line for metastatic prostate cancer

Joe O'Sullivan

Joe O’Sullivan, MD, FRCR, FFRRCSI, FRCPI, of Queen’s University Belfast, Belfast, UK, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, and explains the promising safety results of the AdRad trial that investigated the combination of radium-223 and VMAT radiotherapy in patients presenting with metastatic prostate cancer (NCT00653848).

Share this video